At present, more than 95% of PET studies worldwide are performed in oncologic patients, using F-18 Fluorodeoxyglucose (FDG). But, despite its high diagnostic accuracy in determining the pivotal role in the restaging (and staging) of the neoplasm, FDG is handicapped by false negative and positive results, creating limitations in the differential diagnosis of cancer. Moreover, PET-FDG shares with all the other diagnostic techniques the inability to answer all the questions of the oncologist, the surgeon, and the radiotherapist. It cannot function alone, either in the diagnostic field, or in giving all the information connected with prognosis and pursue a “tailored strategy” for each patient. Therefore, despite its primary role, there is a wide range of indications in oncologic patients that other radiotracers may be useful.
Although [18F]fluorodeoxyglucose (FDG) generally shows an excellent performance as a cancer-imaging agent when using PET-CT, there are some settings in which other radiopharmaceuticals offer advantages. Such non-FDG tracers are now gaining widespread acceptance not only in research but also in clinical practice.
This atlas, including about 500 high-quality images, is a user-friendly guide to PET-CT imaging beyond FDG. A wide range of tracers is covered, such as 18F- and 11C-choline, 11C-methionine, 18F-ethyl-L-tyrosine, 68Ga-DOTA-NOC, 11C-acetate, 11C-thymidine, and 18F-DOPA. Throughout, the emphasis is on image interpretation, with guidance on the recognition of normal, benign, and malignant uptake and clear instruction on learning points and pitfalls. This atlas is designed to serve as a reference text for both nuclear physicians and radiologists, and will also be of great benefit to radiographers, technologists, and nuclear medicine and radiology residents.
Contents
Chapter 1 Importance of Radiotracers Other than FDG in Oncology
Chapter 2 Considerations About PET Isotopes
Chapter 3 Choline PET-CT
Chapter 4 Methionine PET-CT
Chapter 5 Fluoride PET-CT
Chapter 6 Tyrosine PET-CT
Chapter 7 Somatostatin Receptor PET-CT
Chapter 8 Acetate PET-CT
Chapter 9 Thymidine PET-CT
Chapter 10 Dopa PET-CT
Chapter 11 Imaging of Hypoxia with PET-CT
Chapter 12 Angiogenesis PET Using Radiolabeled RGD Peptides
Chapter 13 Hormonal Receptors PET-CT
Chapter 14 HTP PET-CT
Chapter 15 References
Subject Index
Although [18F]fluorodeoxyglucose (FDG) generally shows an excellent performance as a cancer-imaging agent when using PET-CT, there are some settings in which other radiopharmaceuticals offer advantages. Such non-FDG tracers are now gaining widespread acceptance not only in research but also in clinical practice.
This atlas, including about 500 high-quality images, is a user-friendly guide to PET-CT imaging beyond FDG. A wide range of tracers is covered, such as 18F- and 11C-choline, 11C-methionine, 18F-ethyl-L-tyrosine, 68Ga-DOTA-NOC, 11C-acetate, 11C-thymidine, and 18F-DOPA. Throughout, the emphasis is on image interpretation, with guidance on the recognition of normal, benign, and malignant uptake and clear instruction on learning points and pitfalls. This atlas is designed to serve as a reference text for both nuclear physicians and radiologists, and will also be of great benefit to radiographers, technologists, and nuclear medicine and radiology residents.
Contents
Chapter 1 Importance of Radiotracers Other than FDG in Oncology
Chapter 2 Considerations About PET Isotopes
Chapter 3 Choline PET-CT
Chapter 4 Methionine PET-CT
Chapter 5 Fluoride PET-CT
Chapter 6 Tyrosine PET-CT
Chapter 7 Somatostatin Receptor PET-CT
Chapter 8 Acetate PET-CT
Chapter 9 Thymidine PET-CT
Chapter 10 Dopa PET-CT
Chapter 11 Imaging of Hypoxia with PET-CT
Chapter 12 Angiogenesis PET Using Radiolabeled RGD Peptides
Chapter 13 Hormonal Receptors PET-CT
Chapter 14 HTP PET-CT
Chapter 15 References
Subject Index
Book Details
- Paperback: 243 pages
- Publisher: Springer; 1st edition (January 13, 2010)
- Language: English
- ISBN-10: 3540939083
- ISBN-13: 978-3540939085
- Product Dimensions: 14.3 x 7.6 x 0.6 inches